Skip to main content
main-content

Rheumatoid arthritis

Medications

07-06-2019 | Rheumatoid arthritis | News

Predictors of sustained remission/LDA in anti-TNF-treated RA patients identified

Sustained remission and low disease activity remain uncommon in patients with rheumatoid arthritis receiving anti-tumor necrosis factor therapy but can be predicted by several factors, shows an analysis published in Rheumatology.

07-06-2019 | Rheumatoid arthritis | News

Integrated analysis supports safety profile of abatacept in RA

A pooled analysis of data from nine randomized placebo-controlled trials suggests that abatacept has a favorable safety profile among patients with rheumatoid arthritis.

07-06-2019 | Rheumatoid arthritis | Case study | Article

Tofacitinib in a patient with refractory severe rheumatoid arthritis

Paul Emery and John Fitton present the case of a patient who has responded to treatment with the JAK inhibitor tofacitinib as her sixth-line targeted therapy for biologic-refractory rheumatoid arthritis.

Tofacitinib in a patient with refractory severe rheumatoid arthritis

Paul Emery and John Fitton present the case of a patient who has responded to treatment with the JAK inhibitor tofacitinib as her sixth-line targeted therapy for biologic-refractory rheumatoid arthritis.

04-06-2019 | Rheumatoid arthritis | News

Support for TNF inhibitor dose reduction in RA patients with low disease activity

Dose reduction of tumor necrosis factor (TNF) inhibitors may be an appropriate strategy for rheumatoid arthritis patients who achieve low disease activity while receiving full doses of the agents, report the authors of a Cochrane systematic review.

03-06-2019 | Rheumatoid arthritis | Highlight | News

IL-6 receptor inhibition may induce bone erosion repair in RA

Patients with early rheumatoid arthritis who are treated with the interleukin-6 receptor inhibitor tocilizumab experience more pronounced repair of bone erosions than those given adalimumab plus methotrexate, indicate findings from the REBONE study.

IL-6 receptor inhibition may induce bone erosion repair in RA

Patients with early rheumatoid arthritis who are treated with the interleukin-6 receptor inhibitor tocilizumab experience more pronounced repair of bone erosions than those given adalimumab plus methotrexate, indicate findings from the REBONE study.

Opioids, SSRIs, glucocorticoids implicated in RA fracture risk

US research shows that the use of opioids, selective serotonin reuptake inhibitors, or glucocorticoids may increase the risk for all types of osteoporotic fracture in patients with rheumatoid arthritis.

24-05-2019 | Rheumatoid arthritis | Highlight | News

Opioids, SSRIs, glucocorticoids implicated in RA fracture risk

US research shows that the use of opioids, selective serotonin reuptake inhibitors, or glucocorticoids may increase the risk for all types of osteoporotic fracture in patients with rheumatoid arthritis.

Glucocorticoid use may increase infection risk in RA patients undergoing joint replacement

Analysis of two US administrative databases indicates that glucocorticoid use is associated with a dose-dependent increase in postoperative infection risk in patients with rheumatoid arthritis undergoing elective total knee or hip replacement.

21-05-2019 | Rheumatoid arthritis | News

Short-term JAK inhibitor use not linked to increased CV risk

Rheumatoid arthritis patients receiving Janus kinase inhibitors may not be at increased risk for cardiovascular events in the short term, suggests a meta-analysis of randomized controlled trials comparing the active agents with placebo.

20-05-2019 | Rheumatoid arthritis | Highlight | News

Glucocorticoid use may increase infection risk in RA patients undergoing joint replacement

Analysis of two US administrative databases indicates that glucocorticoid use is associated with a dose-dependent increase in postoperative infection risk in patients with rheumatoid arthritis undergoing elective total knee or hip replacement.

17-05-2019 | Rheumatoid arthritis | News

More than two infliximab escalations may be unwarranted in RA

The clinical benefit of infliximab dose escalation in people with rheumatoid arthritis may be limited to the initial two escalations, US study findings indicate.

13-05-2019 | Rheumatoid arthritis | Highlight | News

Switch from adalimumab to baricitinib may benefit some RA patients

Analysis of data from the RA-BEAM and RA-BEYOND trials suggests that switching from adalimumab to baricitinib is associated with improvements in disease control and patient-reported outcomes in patients with rheumatoid arthritis, with an acceptable safety profile.

Switch from adalimumab to baricitinib may benefit some RA patients

Analysis of data from the RA-BEAM and RA-BEYOND trials suggests that switching from adalimumab to baricitinib is associated with improvements in disease control and patient-reported outcomes in patients with rheumatoid arthritis, with an acceptable safety profile.

03-05-2019 | Rheumatoid arthritis | News

Meta-analysis supports increased herpes zoster risk with JAK inhibitors

Findings from a systematic review and meta-analysis indicate that the incidence of herpes zoster among rheumatoid arthritis patients treated with Janus kinase inhibitors is higher than expected in this population, and baricitinib is associated with a significantly increased risk.

01-05-2019 | Rheumatoid arthritis | News

CD40L blockade shows promise for RA

Findings from a proof-of-concept study provide preliminary evidence that the CD40 ligand binding agent VIB4920 may be a promising treatment option for rheumatoid arthritis.

29-04-2019 | Etanercept biosimilar | News

FDA approves etanercept biosimilar

Click through for more information on this announcement

26-04-2019 | Rheumatoid arthritis | News

Namilumab shows promise in phase II trial

Namilumab induces a rapid and sustained clinically significant response in patients with moderate-to-severe rheumatoid arthritis, with a favorable tolerability profile, show results of the phase II NEXUS trial.

24-04-2019 | Rheumatoid arthritis | News

HDL cholesterol levels may predict CV risk in tofacitinib-treated RA patients

Increasing levels of high-density lipoprotein cholesterol are associated with a reduction in cardiovascular risk among rheumatoid arthritis patients undergoing treatment with the Janus kinase inhibitor tofacitinib, researchers report.

Image Credits